Form 4: Director Douglas G. Cole Acquires Foghorn Therapeutics Stock

Director Douglas G. Cole reported the acquisition of 28,000 shares of Foghorn Therapeutics Inc. (FHTX) common stock via stock options.

Summary

• Douglas G. Cole, a Director at Foghorn Therapeutics Inc., acquired 28,000 shares of common stock through the exercise of stock options.
• The transaction occurred on June 24, 2026, with an exercise price of $4.08 per share.
• These options were granted with an exercise price of $4.08 and have an expiration date of June 23, 2036.
• The acquired shares represent a direct beneficial ownership of 28,000 shares following the transaction.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard insider transaction of exercising options, indicating a belief in the current stock value.

Positives

• Director's acquisition of stock options indicates confidence in the company's future prospects.
• The exercise of options at a price of $4.08 suggests the current or anticipated market value is at least this level.

Future Outlook

The filing does not contain forward-looking statements or guidance. The expiration date of the stock options is June 23, 2036.

Industry Context

StockSavvy.ai notes that insider transactions, such as the exercise of stock options by a director, can be interpreted as a signal of management's belief in the company's valuation and future performance within the biotechnology sector.

Stakeholder Impact

• Shareholders may view this as a positive signal of director confidence in the company's stock.
• Employees may interpret this as a sign of internal belief in the company's valuation.

Key Dates

Keywords

Foghorn Therapeutics, FHTX, Form 4, Stock Options, Insider Trading, Beneficial Ownership, Director Transaction